Cabazitaxel in Platinum Refractory Ovarian Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Ovarian Cancer

Interventions

DRUG

Cabazitaxel

25 mg/m2 IV every three weeks

Trial Locations (4)

Department of Oncology, Aalborg Hospital, Aalborg

Herlev Hospital, Herlev

Department of Oncology, Odense University Hospital, Odense

Department of Oncology, Vejle Hospital, Vejle